[HTML][HTML] Alterations of oligodendrocyte and myelin energy metabolism in multiple sclerosis

E López-Muguruza, C Matute - International journal of molecular sciences, 2023‏ - mdpi.com
Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system
(CNS), characterized by demyelination and neurodegeneration. Oligodendrocytes play a …

Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability

AK Carlson, M Amin, JA Cohen - Drugs, 2024‏ - Springer
Currently, there are four monoclonal antibodies (mAbs) that target the cluster of
differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab …

Dietary polyphenols, microbiome, and multiple sclerosis: From molecular anti-inflammatory and neuroprotective mechanisms to clinical evidence

G La Rosa, MS Lonardo, N Cacciapuoti… - International journal of …, 2023‏ - mdpi.com
Multiple sclerosis (MS) is a multifactorial, immune-mediated disease caused by complex
gene-environment interactions. Dietary factors modulating the inflammatory status through …

Whole-Body Cryostimulation in Multiple Sclerosis: A Sco** Review

A Alito, JM Fontana, E Franzini Tibaldeo… - Journal of Clinical …, 2024‏ - mdpi.com
Multiple sclerosis (MS) is the most common cause of non-traumatic long-term disability in
young adults. Whole-body cryostimulation (WBC) is a cold-based physical therapy known to …

Highly effective therapy versus escalation approaches in early multiple sclerosis: what is the future of multiple sclerosis treatment?

NB Rjeily, EM Mowry, D Ontaneda… - Neurologic …, 2024‏ - neurologic.theclinics.com
Multiple sclerosis (MS) is a chronic disease of the central nervous system with a global
prevalence of more than 2 million cases worldwide 1 and nearly one million cases in the US …

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

AJ Coles, A Achiron, A Traboulsee… - Therapeutic …, 2023‏ - journals.sagepub.com
Background and objectives: Alemtuzumab demonstrated superior efficacy versus
subcutaneous interferon (IFN) beta-1a in participants with relapsing-remitting multiple …

Leveraging real-world evidence and observational studies in treating multiple sclerosis

A Aboseif, I Roos, S Krieger, T Kalincik… - Neurologic …, 2024‏ - neurologic.theclinics.com
In a rapidly evolving treatment landscape for multiple sclerosis (MS), the utilization of real-
world observational studies has become increasingly valuable for decisionmaking at the …

[HTML][HTML] Potential Application of Plant-Derived Compounds in Multiple Sclerosis Management

S Woodfin, S Hall, A Ramerth, B Chapple, D Fausnacht… - Nutrients, 2024‏ - mdpi.com
Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by inflammation,
demyelination, and neurodegeneration, resulting in significant disability and reduced quality …

Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis–real-world evidence from Germany

S Papukchieva, AS Stratil, M Kahn… - Therapeutic …, 2024‏ - journals.sagepub.com
Background: While evidence highlights the effectiveness of initiating disease-modifying
therapy with a high-efficacy medication for multiple sclerosis (MS) patients with poor …

Advanced MRI techniques: Diagnosis and follow-up of multiple sclerosis

R Nistri, A Ianniello, V Pozzilli, C Giannì, C Pozzilli - Diagnostics, 2024‏ - mdpi.com
Brain and spinal cord imaging plays a pivotal role in aiding clinicians with the diagnosis and
monitoring of multiple sclerosis. Nevertheless, the significance of magnetic resonance …